Combining Immunotherapy with Anlotinib in Extensive-Stage Small Cell Lung Cancer: A Multicenter Analysis of Efficacy and Safety
Technology in Cancer Research & Treatment · 2025
DOI: 10.1177/15330338251329248 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Technology in Cancer Research & Treatment, 2025. Verfasst von Guogang Gao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, 70 Heping Road, Weihai 264200, Shandong,…. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Indoles, Quinolines, Lung Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Extensive-stage small cell lung cancer (ES-SCLC) is a highly aggressive malignancy with poor prognosis. This study aimed to assess the efficacy of combining immunotherapy (IT) with Anlotinib in ES-SCLC patients.
Methods
This study was a multicenter retrospective cohort analysis. Survival outcomes were evaluated using Kaplan-Meier curves and Cox proportional hazards regression models.
Results
A total of 147 patients were included in the analysis. The median overall survival (mOS) for the cohort was 15.5 months (95% CI: 13.9-17.1). Patients in the chemotherapy(CT) plus IT group had an mOS of 17.8 months, compared to 12.6 months in the CT-alone group (p = 0.055). When stratified into CT + IT + Anlotinib, CT + IT, and CT-alone groups, the mOS were 18.5, 16.3, and 12.6 months, respectively, with the CT + IT + Anlotinib group demonstrating significantly improved OS compared to CT-alone (p = 0.044). The ORR and DCR for the entire cohort were 71.4% and 85.7%, respectively. Subgroup analysis revealed ORRs of 74.1% (CT + IT + Anlotinib), 73.9% (CT + IT), and 70.1% (CT-alone), with corresponding DCRs of 92.6%, 91.3%, and 82.5%. Multivariate analysis revealed that radiotherapy (RT, p = 0.003) and IT (p = 0.021) were independent prognostic factors for OS, while liver metastasis (p = 0.023) and RT (p = 0.018) were associated with PFS. Patients receiving RT in combination with CT showed markedly improved OS (17.5 vs 12.5 months; p = 0.002) and PFS (7.3 vs 6.3 months; p = 0.004). The incidence of adverse events was comparable across all groups (p = 0.721).
Conclusion
The combined application of Anlotinib with IT and the combination of CT with RT both significantly improved survival outcomes in patients with ES-SCLC while maintaining a favorable safety profile. These findings warrant further investigation in future studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, 70 Heping Road, Weihai 264200, Shandong, China.
- Department of Pulmonary and Critical Care Medicine, Qilu Hospital, Cheeloo College of Medicine, Shandong University, No. 107 Wenhua Xilu, Jinan 250012, Shandong, China.
- Department of Respiratory Medicine, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, 70 Heping Road, Weihai 264200, Shandong, China.
- Department of Pulmonary and Critical Care Medicine, Qilu Hospital of Shandong University Dezhou Hospital, 1166 Dong Fang Hong west road, Dezhou, Shandong 253000, China.
- Department of Radiation Oncology,Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, 70 Heping Road, Weihai 264200, Shandong, China.
ORCID-Profile: Guogang Gao, Meiling Sun, Zhongfei Yang, Jingyi Li, Huaijun Ji, Ge Yu
Zitieren
APA
Gao, G., Sun, M., Yang, Z., Li, J., Ji, H., & Yu, G. (2025). Combining Immunotherapy with Anlotinib in Extensive-Stage Small Cell Lung Cancer: A Multicenter Analysis of Efficacy and Safety. Technology in Cancer Research & Treatment. https://doi.org/10.1177/15330338251329248
Vancouver
Gao G, Sun M, Yang Z, Li J, Ji H, Yu G. Combining Immunotherapy with Anlotinib in Extensive-Stage Small Cell Lung Cancer: A Multicenter Analysis of Efficacy and Safety. Technology in Cancer Research & Treatment. 2025. doi:10.1177/15330338251329248
BibTeX
@article{Gao2025,
author = {Gao, Guogang and Sun, Meiling and Yang, Zhongfei and Li, Jingyi and Ji, Huaijun and Yu, Ge},
title = {Combining Immunotherapy with Anlotinib in Extensive-Stage Small Cell Lung Cancer: A Multicenter Analysis of Efficacy and Safety},
journal = {Technology in Cancer Research & Treatment},
year = {2025},
doi = {10.1177/15330338251329248}
}
EUVIMED